Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 931-933

  Poeppl, W ^a   Tobudic, S ^a   Lingscheid, T ^a   Plasenzotti, R ^a   Kozakowski, N ^a   Georgopoulos, A ^a   Burgmann, H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; RAT; TIBIA; TREATMENT DURATION;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; FOSFOMYCIN; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OSTEOMYELITIS; RATS; RATS, SPRAGUE-DAWLEY; STAPHYLOCOCCAL INFECTIONS; TIBIA; TREATMENT OUTCOME;

EID: 78751700060     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00881-10     Document Type: Article

References (27)

1. Alos, J. I., P. Garcia-Pena, and J. Tamayo. 2007. Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections. Rev. Esp. Quimioter. 20:211-215.
2. Cai, Y., Y. Fan, R. Wang, M. M. An, and B. B. Liang. 2009. Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model. J. Antimicrob. Chemother. 64:563-566.
3. Reference deleted.
4. Dagan, R., K. P. Klugman, W. A. Craig, and F. Baquero. 2001. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J. Antimicrob. Chemother. 47:129-140.
5. Dombrowski, J. C., and L. G. Winston. 2008. Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections. J. Infect. 57:110-115.
6. Falagas, M. E., K. P. Giannopoulou, G. N. Kokolakis, and P. I. Rafailidis. 2008. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis. 46:1069-1077.
7. Gould, I. M., and F. M. MacKenzie. 2002. Antibiotic exposure as a risk factor for emergence of resistance: the influence of concentration. Symp. Ser. Soc. Appl. Microbiol. 31:78S-84S.
8. Horii, T., T. Kimura, K. Sato, K. Shibayama, and M. Ohta. 1999. Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26. Antimicrob. Agents Chemother. 43:789-793.
9. Huovinen, P. 2002. Macrolide-resistant group A streptococcus - now in the United States. N. Engl. J. Med. 346:1243-1245.
10. Kazmierczak, A., et al. 1985. Bactericidal activity of cefotaxime and fosfomycin in cerebrospinal fluid during the treatment of rabbit meningitis experimentally induced by methicillin-resistant Staphylococcus aureus. Infection 13(Suppl. 1):S76-S80.
11. Marchese, A., L. Gualco, E. A. Debbia, G. C. Schito, and A. M. Schito. 2003. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int. J. Antimicrob. Agents 22(Suppl. 2):53-59.
12. Meissner, A., R. Haag, and R. Rahmanzadeh. 1989. Adjuvant fosfomycin medication in chronic osteomyelitis. Infection 17:146-151. (Pubitemid 19151438)
13. Mikuniya, T., et al. 2007. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J. Infect. Chemother. 13:285-290.
14. Morikawa, K., M. Nonaka, I. Torii, and S. Morikawa. 2003. Modulatory effect of fosfomycin on acute inflammation in the rat air pouch model. Int. J. Antimicrob. Agents 21:334-339.
15. Morikawa, K., M. Nonaka, Y. Yoshikawa, and I. Torii. 2005. Synergistic effect of fosfomycin and arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm in a rat model. Int. J. Antimicrob. Agents 25:44-50.
16. Nakazawa, H., Y. Kikuchi, T. Honda, T. Isago, and M. Nozaki. 2003. Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin. J. Infect. Chemother. 9:304-309.
17. Popovic, M., D. Steinort, S. Pillai, and C. Joukhadar. 2010. Fosfomycin: an old, new friend? Eur. J. Clin. Microbiol. Infect. Dis. 29:127-142.
18. Reference deleted.
19. Rice, L. B., C. T. Eliopoulos, J. D. Yao, G. M. Eliopoulos, and R. C. Moellering, Jr. 1992. In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model. Diagn. Microbiol. Infect. Dis. 15:173-176.
20. Schintler, M. V., et al. 2009. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J. Antimicrob. Chemother. 64:574-578.
21. Schito, G. C. 2003. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int. J. Antimicrob. Agents 22(Suppl. 2):79-83.
22. Takahata, S., et al. 2010. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int. J. Antimicrob. Agents 35:333-337.
23. Reference deleted.
24. Reference deleted.
25. Wittmann, D. 1980. Chemotherapeutic principles of difficult-to-treat infections in surgery: bone and joint infections. Infection 8:330-333. (Pubitemid 12183913)
26. Yin, L. Y., J. H. Calhoun, J. K. Thomas, S. Shapiro, and A. Schmitt-Hoffmann. 2008. Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:1618-1622.
27. Zak, O., et al. 1982. Experimental staphylococcal osteomyelitis in rats: therapy with rifampin and cloxacillin alone or in combination, p. 973-974. In P. Perti and G. Grassi (ed.) Current chemotherapy and immunotherapy. American Society for Microbiology, Washington, DC.